Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Slams Dutch IP Policy

US Embassy Attacks Over Compulsory Licensing And Compounding

Executive Summary

The US embassy in the Netherlands has attacked Dutch policies on compulsory licensing and compounding. Critics have accused it of scaremongering.

You may also be interested in...



Dutch Hospital Resumes Own Manufacture Of Leadiant’s Costly Drug

While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.

The Netherlands Swaps Germany For Norway To Set Prices

The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices. 

Compulsory Licensing And Compounded Orkambi: Solutions For Excessive Prices In The Netherlands?

Compulsory licensing, new R&D models, and pharmaceutical compounding are among measures that could help secure lower drugs prices, according to a report from the Dutch Council for Public Health and Society.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel